Modality
Radioligand
MOA
CGRPant
Target
EZH2
Pathway
Proteasome
MMAsthmaUrothelial Ca
Development Pipeline
Preclinical
~Apr 2013
→ ~Jul 2014
Phase 1
~Oct 2014
→ ~Jan 2016
Phase 2
~Apr 2016
→ ~Jul 2017
Phase 3
Oct 2017
→ Oct 2028
Phase 3Current
NCT06211266
1,084 pts·MM
2020-07→TBD·Terminated
NCT07365336
1,967 pts·MM
2023-04→2028-10·Terminated
NCT08854364
2,836 pts·MM
2017-10→2025-07·Active
+1 more trial
7,327 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-07-198mo agoPh3 Readout· MM
2026-07-204mo awayPh3 Readout· MM
2028-10-232.6y awayPh3 Readout· MM
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P3
Active
P3
Recruit…
P3
Termina…
P3
Termina…
Catalysts
Ph3 Readout
2025-07-19 · 8mo ago
MM
Ph3 Readout
2026-07-20 · 4mo away
MM
Ph3 Readout
2028-10-23 · 2.6y away
MM
RecruitingActiveTerminated|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06211266 | Phase 3 | MM | Terminated | 1084 | LiverFat |
| NCT07365336 | Phase 3 | MM | Terminated | 1967 | EASI-75 |
| NCT08854364 | Phase 3 | MM | Active | 2836 | ORR |
| NCT08500309 | Phase 3 | MM | Recruiting | 1440 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Rilufotisoran | Samsung Biologics | NDA/BLA | FXIa |